BIOMAT Database Logo BIOMAT Database Logo

Restricted oncogenicity of BCR/ABL p190 in transgenic mice. 1992

J W Voncken, and S Griffiths, and M F Greaves, and P K Pattengale, and N Heisterkamp, and J Groffen
Section of Molecular Diagnosis, Childrens Hospital, Los Angeles, California 90027.

A chimeric BCR/ABL oncogene encoding the p190 protein has been introduced into the mouse germline using microinjection of one-cell fertilized eggs. Founder and progeny transgenic animals, when becoming ill, were found to develop lymphoblastic leukemia/lymphoma which was transplantable to compatible recipients. Lymphoblasts were arrested at the pre-B stage of development. Expression of BCR/ABL was not detected in peripheral blood during the early stages of leukemia but became evident as the disease progressed. However, the transgene was expressed early in development in bone marrow and was also transcribed in nonhematopoietic tissues although this did not result in tumorigenesis. These results strongly suggest that the oncogenicity of BCR/ABL is limited to hematopoietic cells, including pre-B cells or their progenitors.

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011519 Proto-Oncogenes Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc. Proto-Oncogene,Proto Oncogene,Proto Oncogenes
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002678 Chimera An individual that contains cell populations derived from different zygotes. Hybrids,Chimeras,Hybrid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012334 RNA, Neoplasm RNA present in neoplastic tissue. Neoplasm RNA

Related Publications

J W Voncken, and S Griffiths, and M F Greaves, and P K Pattengale, and N Heisterkamp, and J Groffen
The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice.
April 2001, International journal of molecular medicine,
J W Voncken, and S Griffiths, and M F Greaves, and P K Pattengale, and N Heisterkamp, and J Groffen
Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice.
February 2001, Cancer research,
J W Voncken, and S Griffiths, and M F Greaves, and P K Pattengale, and N Heisterkamp, and J Groffen
IFN-alpha treatment of p190 bcr abl transgenic mice.
July 1994, International journal of oncology,
J W Voncken, and S Griffiths, and M F Greaves, and P K Pattengale, and N Heisterkamp, and J Groffen
BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
December 1995, Blood,
J W Voncken, and S Griffiths, and M F Greaves, and P K Pattengale, and N Heisterkamp, and J Groffen
Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.
September 2000, Blood,
J W Voncken, and S Griffiths, and M F Greaves, and P K Pattengale, and N Heisterkamp, and J Groffen
BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
May 2002, Oncogene,
J W Voncken, and S Griffiths, and M F Greaves, and P K Pattengale, and N Heisterkamp, and J Groffen
The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
November 2002, Leukemia research,
J W Voncken, and S Griffiths, and M F Greaves, and P K Pattengale, and N Heisterkamp, and J Groffen
Acute leukaemia in bcr/abl transgenic mice.
March 1990, Nature,
J W Voncken, and S Griffiths, and M F Greaves, and P K Pattengale, and N Heisterkamp, and J Groffen
Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.
March 2001, Blood,
J W Voncken, and S Griffiths, and M F Greaves, and P K Pattengale, and N Heisterkamp, and J Groffen
Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes.
May 2000, British journal of haematology,
Copied contents to your clipboard!